Jefferson Headache Center,Philadelphia,Pennsylvania,USA.
CNS Spectr. 2017 Dec;22(S1):1-13. doi: 10.1017/S1092852917000864.
Migraine varies in its frequency, severity, and impact; treatment should consider these variations and the patient's needs and goals. Migraine pharmacologic treatment may be acute (abortive) or preventive (prophylactic), and patients often require both. New medication devices are available or in development, including an intracutaneous, microneedle system of zolmitriptan and sumatriptan, and breath-powered powder sumatriptan intranasal treatment. Lasmiditan, a 5-HT1F receptor agonist, is in development for acute treatment, as are small molecule calcitonin gene-related peptide (CGRP) receptor antagonists (Gepants) for acute and preventive treatment. Antibodies to CGRP and its receptor are being developed for migraine prevention. All 4 treatments are effective and have, as of yet, no safety concerns.
偏头痛的频率、严重程度和影响各不相同；治疗应考虑这些差异以及患者的需求和目标。偏头痛的药物治疗可能是急性（终止）或预防（预防性）的，患者通常两者都需要。新的药物设备正在开发或已经上市，包括一种曲普坦和舒马曲坦的皮内微针系统，以及呼吸驱动的粉末舒马曲坦鼻内治疗。利扎曲坦是一种 5-HT1F 受体激动剂，正在开发用于急性治疗，小分子降钙素基因相关肽 (CGRP) 受体拮抗剂（ gepants）也在开发用于急性和预防性治疗。针对 CGRP 及其受体的抗体也在开发中，用于偏头痛预防。所有 4 种治疗方法都有效，到目前为止，没有安全问题。
